Skip to content

Study on transdermal absorption and whitening mechanism of traditional Chinese medicine ingredients in Yurong whitening essence

Study on transdermal absorption and whitening mechanism of traditional Chinese medicine ingredients in Yurong whitening essence

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062085
Enrollment
Unknown
Registered
2022-07-21
Start date
2022-07-22
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial pigmentation

Interventions

2:Yurong whitening essence,1ml/ time, 2 times / day

Sponsors

Ji'nan Municipal Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 20-60 years;2. Skin problems such as aging and rough facial skin, dark and yellowish complexion, and lack of luster are caused by various reasons, excluding facial skin changes caused by other diseases; 3. The ITA° value of skin brightness detected by dermatoscopy is 11° - 45°; 4.No other treatment for face; 5. No history of skin allergy;6. Be able to understand and cooperate with the requirements, objectives, and methods of this study, participate voluntarily, follow the doctor's advice during the treatment process, and sign the informed consent independently.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Scar constitution and allergic constitution; 3. Complicated with heart, lung, liver, kidney, hematopoietic system, malignant tumor, infectious disease, and other serious diseases;4. Exclude other diseases (such as naevus fuscocyanus zygomaticus, Riel melanosis, pigmented lichen planus, freckles, coffee spots, post-inflammatory pigmentation, nevus of Ota, etc.); 5. Oral or local use of whitening drugs within 3 months; 6. Use photon or laser whitening within 6 months; 7. Patients who are taking drugs that may affect their complexion (contraceptives, thyroxine, estrogen), photosensitive drugs; 8. Combined with a bacterial and fungal infection, or local skin damage and superficial ulcer; 9. Those who are taking anticoagulant drugs and have coagulation dysfunction; 10. Patients with autoimmune diseases (such as dermatomyositis, systemic lupus erythematosus, pemphigus, etc.) and mental disorders.

Design outcomes

Primary

MeasureTime frame
ITA°;

Secondary

MeasureTime frame
Facial pigmentation area;Skin wrinkle score;

Countries

China

Contacts

Public ContactTao Haiyan
taohaiyan115@163.com+86 13285314292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026